Avis Budget Group, Inc. (CAR) Income Statement Analysis

See more : Nichi-Iko Pharmaceutical Co., Ltd. (4541.T) Income Statement Analysis – Financial Results

Complete financial analysis of Avis Budget Group, Inc. (CAR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avis Budget Group, Inc., a leading company in the Rental & Leasing Services industry within the Industrials sector.

You may be interested

Avis Budget Group, Inc. (CAR)

Industry: Rental & Leasing Services

Sector: Industrials

Website: https://www.avisbudgetgroup.com

About Avis Budget Group, Inc.

Avis Budget Group, Inc., together with its subsidiaries, provides car and truck rentals, car sharing, and ancillary products and services to businesses and consumers. It operates the Avis brand, that offers vehicle rental and other mobility solutions to the premium commercial and leisure segments of the travel industry; the Budget Truck brand, a local, and one-way truck and cargo van rental businesses with a fleet of approximately 20,000 vehicles, which are rented through a network of approximately 465 dealer-operated and 385 company-operated locations that serve the consumer and light commercial sectors in the continental United States; and the Zipcar brand, a car sharing network. The company also operates various other car rental brands, such as Budget, Payless, Apex, Maggiore, MoriniRent, FranceCars, Amicoblue, Turiscar, and ACL Hire. In addition, it offers optional insurance products and coverages, such as supplemental liability, personal accident, personal effects protection, emergency sickness protection, and automobile towing protection and cargo insurance products; fuel service options, roadside assistance services, electronic toll collection services, curbside delivery, tablet rentals, access to satellite radio, portable navigation units, and child safety seat rentals; automobile towing equipment and other moving accessories, such as hand trucks, furniture pads, and moving supplies; and Business Intelligence solution, an online portal for corporate travel. Avis Budget Group, Inc. operates in approximately 10,400 locations worldwide. The company was formerly known as Cendant Corporation and changed its name to Avis Budget Group, Inc. in September 2006. Avis Budget Group, Inc. was founded in 1946 and is headquartered in Parsippany, New Jersey.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Revenue	12.01B	11.99B	9.31B	5.40B	9.17B	9.12B	8.85B	8.66B	8.50B	8.49B	7.94B	7.36B	5.90B	5.19B	5.13B	5.98B	6.03B	5.69B	18.24B	19.79B	18.19B	14.09B	8.95B	3.93B	5.40B	5.28B	5.31B	2.35B	1.42B	1.04B	875.00M	738.90M	641.30M	450.80M	365.00M	268.60M	195.30M	138.30M	84.20M
Cost of Revenue	7.24B	1.23B	1.51B	1.69B	2.41B	2.49B	2.51B	2.33B	2.22B	2.29B	2.08B	1.77B	1.51B	1.59B	1.72B	2.01B	1.93B	1.74B	10.68B	10.34B	9.41B	6.72B	2.94B	1.31B	1.10B	609.20M	-184.00M	-3.00M	-74.00M	-95.70M	-94.70M	-109.10M	-106.70M	-73.00M	128.50M	10.40M	16.90M	900.00K	2.40M
Gross Profit	4.77B	10.76B	7.80B	3.72B	6.77B	6.63B	6.34B	6.33B	6.28B	6.21B	5.86B	5.59B	4.39B	3.59B	3.41B	3.97B	4.10B	3.95B	7.55B	9.45B	8.78B	7.37B	6.01B	2.62B	4.31B	4.67B	5.50B	2.35B	1.49B	1.14B	969.70M	848.00M	748.00M	523.80M	236.50M	258.20M	178.40M	137.40M	81.80M
Gross Profit Ratio	39.69%	89.74%	83.79%	68.79%	73.76%	72.68%	71.67%	73.08%	73.86%	73.09%	73.86%	75.97%	74.42%	69.32%	66.50%	66.35%	68.04%	69.48%	41.41%	47.75%	48.28%	52.29%	67.18%	66.56%	79.69%	88.47%	103.46%	100.13%	105.23%	109.16%	110.82%	114.77%	116.64%	116.19%	64.79%	96.13%	91.35%	99.35%	97.15%
Research & Development	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	1.49B	1.28B	1.06B	703.00M	1.24B	1.22B	1.12B	1.13B	1.09B	1.08B	1.02B	925.00M	756.00M	583.00M	551.00M	655.00M	658.00M	818.00M	3.78B	3.58B	3.12B	2.51B	2.01B	1.07B	1.69B	1.82B	0.00	0.00	764.30M	571.10M	489.50M	437.00M	386.90M	270.50M	50.50M	142.00M	100.70M	79.80M	49.60M
Selling & Marketing	-81.00M	64.00M	81.00M	54.00M	121.00M	116.00M	111.00M	127.00M	123.00M	112.00M	116.00M	127.00M	0.00	-14.00M	0.00	0.00	0.00	0.00	1.71B	2.01B	1.76B	1.39B	1.11B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	1.41B	1.35B	1.15B	703.00M	1.24B	1.22B	1.12B	1.13B	1.09B	1.08B	1.02B	925.00M	756.00M	569.00M	551.00M	655.00M	658.00M	818.00M	3.78B	3.58B	3.12B	2.51B	2.01B	1.07B	1.69B	1.82B	1.99B	1.20B	764.30M	571.10M	489.50M	437.00M	386.90M	270.50M	50.50M	142.00M	100.70M	79.80M	49.60M
Other Expenses	0.00	5.51B	4.53B	3.54B	4.95B	4.90B	4.75B	4.61B	4.50B	4.43B	4.23B	3.95B	3.12B	2.71B	2.73B	3.24B	3.12B	2.99B	1.57B	3.06B	3.01B	2.56B	2.30B	330.00M	1.07B	1.58B	2.00B	704.30M	453.90M	378.80M	337.60M	309.50M	277.60M	210.80M	158.30M	132.60M	47.10M	42.30M	24.30M
Operating Expenses	1.58B	6.86B	5.67B	4.25B	6.19B	6.05B	5.81B	5.68B	5.54B	5.51B	5.22B	4.86B	3.88B	3.28B	3.27B	3.89B	3.78B	3.81B	5.35B	6.64B	6.13B	5.07B	4.31B	1.40B	2.76B	3.41B	3.99B	1.90B	1.22B	949.90M	827.10M	746.50M	664.50M	481.30M	208.80M	274.60M	147.80M	122.10M	73.90M
Cost & Expenses	8.82B	8.09B	7.18B	5.93B	8.59B	8.55B	8.31B	8.02B	7.76B	7.80B	7.30B	6.63B	5.39B	4.87B	4.98B	5.90B	5.70B	5.55B	16.03B	16.97B	15.54B	11.79B	7.25B	2.72B	3.85B	4.02B	3.81B	1.90B	1.14B	854.20M	732.40M	637.40M	557.80M	408.30M	337.30M	285.00M	164.70M	123.00M	76.30M
Interest Income	0.00	1.00M	1.00M	12.00M	15.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	296.00M	250.00M	218.00M	231.00M	178.00M	188.00M	188.00M	203.00M	194.00M	209.00M	228.00M	268.00M	219.00M	162.00M	153.00M	129.00M	127.00M	236.00M	1.34B	251.00M	797.00M	1.27B	1.84B	401.00M	3.93B	1.46B	2.36B	340.80M	8.70M	0.00	0.00	2.10M	60.80M	11.00M	15.70M	0.00	0.00	0.00	0.00
Depreciation & Amortization	3.45B	2.81B	2.48B	2.56B	3.14B	2.23B	2.21B	2.13B	163.00M	2.02B	128.00M	109.00M	95.00M	90.00M	96.00M	1.73B	1.65B	1.47B	1.29B	3.20B	3.46B	2.72B	2.17B	330.00M	1.07B	1.58B	2.00B	704.30M	453.90M	378.80M	337.60M	309.50M	277.60M	210.80M	158.30M	132.60M	47.10M	42.30M	24.30M
EBITDA	6.43B	7.15B	4.74B	2.17B	3.96B	2.99B	2.88B	2.98B	794.00M	2.92B	477.00M	693.00M	350.00M	332.00M	172.00M	841.00M	1.10B	1.35B	1.73B	1.31B	6.18B	5.01B	3.88B	1.64B	4.54B	3.69B	4.65B	1.32B	729.00M	569.30M	475.90M	407.70M	383.50M	250.60M	187.80M	116.20M	74.50M	54.10M	31.30M
EBITDA Ratio	53.57%	34.50%	25.80%	-5.72%	8.57%	8.46%	8.31%	9.68%	10.62%	31.98%	9.69%	11.42%	10.34%	7.89%	4.74%	30.17%	32.76%	28.30%	24.39%	30.30%	33.95%	38.23%	51.73%	41.78%	84.04%	69.80%	87.55%	56.28%	51.52%	54.49%	54.39%	55.18%	59.80%	55.59%	51.45%	42.07%	38.15%	39.12%	37.17%
Operating Income	3.19B	3.91B	2.13B	-529.00M	579.00M	516.00M	476.00M	585.00M	685.00M	696.00M	617.00M	715.00M	515.00M	305.00M	129.00M	76.00M	325.00M	143.00M	866.00M	2.80B	2.71B	1.03B	2.46B	1.31B	3.47B	2.11B	2.66B	617.00M	275.10M	190.50M	138.30M	98.20M	105.90M	39.80M	29.50M	-19.60M	27.40M	11.80M	7.00M
Operating Income Ratio	26.57%	32.62%	22.88%	-9.79%	6.31%	5.66%	5.38%	6.76%	8.06%	8.20%	7.77%	9.72%	8.73%	5.88%	2.51%	1.27%	5.39%	2.51%	4.75%	14.15%	14.92%	7.30%	27.51%	33.38%	64.25%	39.85%	49.99%	26.28%	19.44%	18.23%	15.81%	13.29%	16.51%	8.83%	8.08%	-7.30%	14.03%	8.53%	8.31%
Total Other Income/Expenses	-1.28B	-270.00M	-423.00M	-965.00M	-280.00M	-499.00M	-623.00M	-606.00M	-303.00M	-577.00M	-520.00M	-415.00M	-479.00M	-247.00M	-206.00M	-1.42B	-1.32B	-820.00M	-213.00M	1.77B	-445.00M	-700.00M	-1.05B	-354.00M	-2.18B	-1.00B	-754.70M	-170.40M	-4.40M	0.00	-400.00K	-5.40M	-38.40M	-13.70M	-13.90M	1.80M	4.00M	4.30M	-700.00K
Income Before Tax	1.91B	3.64B	1.71B	-956.00M	287.00M	267.00M	211.00M	279.00M	382.00M	392.00M	97.00M	300.00M	36.00M	72.00M	-77.00M	-1.34B	-992.00M	-677.00M	1.35B	2.55B	2.21B	1.64B	658.00M	885.00M	-635.00M	264.40M	294.70M	276.20M	266.40M	190.50M	142.20M	96.10M	45.10M	28.80M	13.80M	-14.60M	31.40M	16.10M	7.20M
Income Before Tax Ratio	15.94%	30.32%	18.34%	-17.70%	3.13%	2.93%	2.38%	3.22%	4.49%	4.62%	1.22%	4.08%	0.61%	1.39%	-1.50%	-22.47%	-16.46%	-11.90%	7.38%	12.88%	12.15%	11.62%	7.35%	22.52%	-11.75%	5.00%	5.54%	11.76%	18.83%	18.23%	16.25%	13.01%	7.03%	6.39%	3.78%	-5.44%	16.08%	11.64%	8.55%
Income Tax Expense	279.00M	880.00M	425.00M	-272.00M	-15.00M	102.00M	-150.00M	116.00M	69.00M	147.00M	81.00M	10.00M	65.00M	18.00M	-30.00M	-219.00M	-45.00M	-226.00M	474.00M	728.00M	745.00M	556.00M	235.00M	309.00M	-406.00M	104.50M	239.30M	112.10M	103.00M	72.90M	54.80M	37.30M	20.00M	11.30M	5.70M	-3.30M	14.00M	7.40M	4.40M
Net Income	1.63B	2.76B	1.29B	-684.00M	302.00M	165.00M	361.00M	163.00M	313.00M	245.00M	16.00M	290.00M	-29.00M	54.00M	-47.00M	-1.12B	-916.00M	-1.99B	1.34B	2.08B	1.17B	846.00M	385.00M	602.00M	-55.00M	539.60M	55.40M	164.10M	163.40M	117.60M	87.40M	58.80M	25.10M	17.50M	8.10M	-11.30M	17.40M	8.70M	2.80M
Net Income Ratio	13.59%	23.04%	13.80%	-12.66%	3.29%	1.81%	4.08%	1.88%	3.68%	2.89%	0.20%	3.94%	-0.49%	1.04%	-0.92%	-18.81%	-15.20%	-35.05%	7.35%	10.52%	6.44%	6.01%	4.30%	15.32%	-1.02%	10.21%	1.04%	6.99%	11.55%	11.26%	9.99%	7.96%	3.91%	3.88%	2.22%	-4.21%	8.91%	6.29%	3.33%
EPS	42.61	58.44	19.80	-9.70	4.02	2.08	4.32	1.78	3.02	2.32	0.15	2.72	-0.28	0.53	-0.46	-11.03	-8.88	-19.82	15.56	20.29	11.50	7.57	4.20	8.40	-0.73	6.40	-2.70	4.10	5.60	4.50	3.40	2.50	1.10	1.00	0.50	-0.70	1.20	0.70	0.20
EPS Diluted	42.06	57.11	19.44	-9.70	3.99	2.06	4.25	1.75	2.98	2.22	0.15	2.42	-0.28	0.49	-0.46	-11.03	-8.88	-19.82	15.56	19.66	11.30	7.57	4.10	8.10	-0.73	6.10	-2.70	4.10	5.60	4.50	3.40	2.50	1.10	1.00	0.50	-0.70	1.20	0.70	0.20
Weighted Avg Shares Out	38.30M	47.30M	64.90M	70.50M	75.20M	79.30M	83.40M	92.00M	103.40M	105.40M	107.60M	106.60M	105.20M	103.10M	102.20M	101.90M	103.10M	100.60M	104.00M	103.10M	101.91M	111.76M	91.67M	71.67M	75.10M	84.38M	80.44M	40.02M	29.18M	26.13M	25.71M	23.52M	22.82M	17.50M	16.20M	16.14M	14.50M	12.43M	14.00M
Weighted Avg Shares Out (Dil)	38.80M	48.40M	66.10M	70.50M	75.70M	80.10M	84.80M	93.30M	105.00M	110.60M	111.40M	121.60M	105.20M	126.70M	102.20M	101.90M	103.10M	100.60M	104.00M	103.10M	103.72M	111.76M	93.90M	74.32M	75.10M	88.52M	80.44M	40.02M	29.18M	26.13M	25.71M	23.52M	22.82M	17.50M	16.20M	16.14M	14.50M	12.43M	14.00M

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma

September 4, 2024prnewswire.com

Reactivation of P-BCMA-101 CAR-T cells and a repeat stringent complete response (sCR) more than 3 years after original CAR-T therapy Demonstrates potential of stem cell memory T cells (TSCM), a key differentiator for Poseida's CAR-T programs SAN DIEGO , Sept. 4,...

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium

September 3, 2024prnewswire.com

SAN JOSE, Calif. , Sept. 3, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the inventor of its ovarian cancer CAR-T technology, Jose...

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

September 3, 2024globenewswire.com

Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

August 26, 2024seekingalpha.com

Allogene Therapeutics is a clinical-stage biotech developing allogeneic CAR T therapies for cancer and autoimmune diseases, with a focus on Cema-cel for LBCL. ALLO's advanced gene-editing platforms, like TALEN and CRISPR/Cas9, engineer donor-derived T cells to overcome autologous therapy limitations,...

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

August 23, 2024seekingalpha.com

Galapagos NV achieved positive results from its European phase 1/2 ATLANTA-1 study using GLPG5101 for patients with relapsed/refractory NHL; phase 1 portion with 87.5% ORR and phase 2 portion with 93.3% ORR. The global non-Hodgkin Lymphoma market is expected to...

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

August 23, 2024globenewswire.com

Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos' Investigational New Drug (IND) application for ATALANTA-1, a...

Canadian Apartment Properties: We Still Prefer Northview When Playing The North

August 21, 2024seekingalpha.com

CAPREIT's operational performance remains solid, but Northview Residential REIT offers a more attractive risk/return profile in the Canadian residential REIT sector. Earnings update shows solid AMR growth in the residential portfolio, NOI growth, and announcement of MHC portfolio sale. CAPREIT...

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

August 12, 2024globenewswire.com

Marker Therapeutics to receive non-dilutive funding from NIH Small Business Innovation Research Program based on preliminary clinical results and non-clinical data in lymphoma Marker Therapeutics to receive non-dilutive funding from NIH Small Business Innovation Research Program based on preliminary clinical...

Canadian Apartment Properties Real Estate Investment Trust (CDPYF) Q2 2024 Earnings Call Transcript

August 10, 2024seekingalpha.com

Canadian Apartment Properties Real Estate Investment Trust (OTC:CDPYF) Q2 2024 Earnings Conference Call August 8, 2024 9:00 AM ET Company Participants Nicole Dolan - Investor Relations Mark Kenney - President and Chief Executive Officer Julian Schonfeldt - Chief Investment Officer...